Avantor Faces Securities Class Action as Stock Plummets Over 23%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Businesswire
- Investigation Launched: Faruqi & Faruqi LLP is investigating potential securities fraud claims against Avantor, urging investors to apply for lead plaintiff status by December 29, 2025, highlighting serious concerns regarding the company's governance and transparency.
- Performance Decline: Avantor reported disappointing first-quarter results in 2025, lowering its full-year guidance, which led to a 16.5% drop in stock price on April 25, 2025, reflecting a significant loss of market confidence in the company's competitive positioning.
- Ongoing Competitive Pressure: The company again reported poor second-quarter results in 2025, projecting organic revenue growth of -2% to 0%, admitting that the competitive environment is not expected to improve, further eroding investor confidence and causing a 15% stock price decline.
- Massive Impairment Loss: In the third quarter of 2025, Avantor reported a net loss of $712 million, primarily due to a $785 million goodwill impairment charge, indicating severe financial strain from competitive pressures, resulting in a 23% drop in stock price.
AVTR
$11.335+Infinity%1D
Analyst Views on AVTR
Wall Street analysts forecast AVTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTR is 13.86 USD with a low forecast of 12.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 11.430
Low
12.00
Averages
13.86
High
17.00
Current: 11.430
Low
12.00
Averages
13.86
High
17.00
About AVTR
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
